Can ADP Ribosylation Serve as a Therapeutic Target?
Given its central role in cellular processes, ADP ribosylation is a promising target for therapeutic intervention. PARP inhibitors are already in use for treating certain types of cancer, exploiting the concept of synthetic lethality in cells deficient in specific DNA repair pathways. Additionally, research is ongoing to develop inhibitors that target bacterial ADP-ribosylating toxins, potentially leading to new treatments for infections by bacteria such as Vibrio cholerae and Corynebacterium diphtheriae.
